Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.51 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 10/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29498319 | 0.93 | DAO (0.53) | DAOAXLNUDT1RIPK1CA12 | |
| SCHEMBL126973 | 0.93 | DAO (0.53) | DAOAXLNUDT1RIPK1CA12 | |
| Fluoride SCHEMBL28140380 | 0.91 | DAO (0.51) | DAOAXLNUDT1RIPK1CA12 | |
| Charcoal, Activated SCHEMBL7531966 | 0.91 | DAO (0.51) | DAOAXLNUDT1RIPK1CA12 | |
| SCHEMBL30213497 | 0.91 | DAO (0.51) | DAOAXLNUDT1RIPK1CA12 | |
| Hydrochloric Acid SCHEMBL29691659 | 0.91 | DAO (0.51) | DAOAXLNUDT1RIPK1CA12 | |
| Bromide SCHEMBL2820333 | 0.91 | DAO (0.51) | DAOAXLNUDT1RIPK1CA12 | |
| Hydrochloric Acid SCHEMBL7181738 | 0.91 | DAO (0.51) | DAOAXLNUDT1RIPK1CA12 | |
| Phosphoric Acid SCHEMBL31544068 | 0.88 | DAO (0.50) | DAOAXLNUDT1RIPK1CA12 | |
| Phosphoric Acid SCHEMBL29264269 | 0.88 | DAO (0.50) | DAOAXLNUDT1RIPK1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105479-A1 | 4-Oxo-1-3-Substituted Phenyl-1,4-Dihydro-1,8-Napthyridene-3-Carboxamide Phosphodiesterase-4 Inhibitor and a Method of Preparing Same | MERCK & CO., INC. (US) | 2009-04-23 | — | — | US | disclosed |
| EP-1981885-A2 | A METHOD OF PREPARING A 4-OXO-1-(3-SUBSTITUTED PHENYL)-1,4-DIHYDRO-1,8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITOR | Merck & Co., Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1951722-A1 | A 4-OXO-1- (3-SUBSTITUTED PHENYL) -1, 4-DIHYDRO-1, 8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4-INHIBITOR AND A METHOD OF PREPARING SAME | Merck Frosst Canada Ltd. (CA) | 2008-08-06 | — | — | EP | disclosed |
| US-20080070940-A1 | 4-Oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitor and a method of preparing same | DUBE DANIEL | 2008-03-20 | — | — | US | disclosed |
| WO-2007048225-A1 | A 4-OXO-1- (3-SUBSTITUTED PHENYL) -1, 4-DIHYDRO-1, 8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4-INHIBITOR AND A METHOD OF PREPARING SAME | MERCK FROSST CANADA LTD. (CA) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007050576-A2 | A METHOD OF PREPARING A 4-OXO-1- (3 SUBSTITUTED PHENYL) -1, 4-DIHYDRO-1, 8-NAPHTHYRIDINE-3- CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITOR | MERCK & CO., INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070099951-A1 | 4-oxo-1-(3-substituted phenyl)-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitor and a method of preparing same | DUBE DANIEL | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099951-A1 | 4-oxo-1-(3-substituted phenyl)-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitor and a method of preparing same | PDE4A, PDE12, PDE4B | DAO 439/4885AXL 4467/4885NUDT1 115/4885 |
| US-20080070940-A1 | 4-Oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitor and a method of preparing same | PDE4A, PDE12, PDE4B | DAO 444/4885AXL 4141/4885NUDT1 109/4885 |
| US-20090105479-A1 | 4-Oxo-1-3-Substituted Phenyl-1,4-Dihydro-1,8-Napthyridene-3-Carboxamide Phosphodiesterase-4 Inhibitor and a Method of Preparing Same | PDE12, PDE4A, PDE4B | DAO 395/4885AXL 4293/4885NUDT1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.